雷珠单抗与阿柏西普治疗视网膜中央静脉阻塞所致黄斑水肿的比较。 - Suppr

Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion.

作者信息

Chatziralli Irini, Theodossiadis George, Theodossiadis Panagiotis

机构信息

2nd Department of Ophthalmology, Attikon Hospital, University of Athens, Athens, Greece.

, 28, Papanastasiou street, Agios Dimitrios, Athens, 17342, Greece.

出版信息

Graefes Arch Clin Exp Ophthalmol. 2017 Jul;255(7):1459-1460. doi: 10.1007/s00417-017-3682-1. Epub 2017 May 8.

DOI:10.1007/s00417-017-3682-1

PMID:28484833

Abstract

摘要

相似文献

Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion.

Graefes Arch Clin Exp Ophthalmol. 2017 Jul;255(7):1459-1460. doi: 10.1007/s00417-017-3682-1. Epub 2017 May 8.

The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion.

Klin Monbl Augenheilkd. 2015 Apr;232(4):552-5. doi: 10.1055/s-0035-1545783. Epub 2015 Apr 22.

Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.

Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1093-1100. doi: 10.1007/s00417-017-3613-1. Epub 2017 Feb 18.

Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab.

Retina. 2014 Dec;34(12):2439-43. doi: 10.1097/IAE.0000000000000238.

Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.

Jpn J Ophthalmol. 2017 Jan;61(1):67-73. doi: 10.1007/s10384-016-0476-7. Epub 2016 Sep 22.

Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.

Graefes Arch Clin Exp Ophthalmol. 2017 Jul;255(7):1455-1457. doi: 10.1007/s00417-017-3681-2. Epub 2017 May 3.

Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.

Ophthalmic Res. 2015;54(3):150-6. doi: 10.1159/000439223. Epub 2015 Sep 29.

Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab.

Int Ophthalmol. 2018 Feb;38(1):207-213. doi: 10.1007/s10792-017-0512-8. Epub 2017 Apr 12.

Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion.

Can J Ophthalmol. 2016 Oct;51(5):342-347. doi: 10.1016/j.jcjo.2016.02.001. Epub 2016 Sep 3.

Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: A UK Healthcare Perspective.

Adv Ther. 2016 Jan;33(1):116-28. doi: 10.1007/s12325-015-0279-0. Epub 2016 Jan 8.

引用本文的文献

Multimodal OCT Reflectivity Analysis of the Cystoid Spaces in Cystoid Macular Edema.

Biomed Res Int. 2019 Mar 20;2019:7835372. doi: 10.1155/2019/7835372. eCollection 2019.

本文引用的文献

RANIBIZUMAB FOR RETINAL VEIN OCCLUSION: Predictive Factors and Long-Term Outcomes in Real-Life Data.

Retina. 2018 Mar;38(3):559-568. doi: 10.1097/IAE.0000000000001579.

Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.

Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1093-1100. doi: 10.1007/s00417-017-3613-1. Epub 2017 Feb 18.

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.

Ophthalmology. 2016 Jun;123(6):1351-9. doi: 10.1016/j.ophtha.2016.02.022. Epub 2016 Feb 27.

Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.

Am J Ophthalmol. 2014 Nov;158(5):1032-8. doi: 10.1016/j.ajo.2014.07.027. Epub 2014 Jul 25.

Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.

Ophthalmology. 2014 Jul;121(7):1414-1420.e1. doi: 10.1016/j.ophtha.2014.01.027. Epub 2014 Mar 27.

Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.

Ophthalmology. 2011 Oct;118(10):2041-9. doi: 10.1016/j.ophtha.2011.02.038. Epub 2011 Jun 29.

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

N Engl J Med. 1994 Dec 1;331(22):1480-7. doi: 10.1056/NEJM199412013312203.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献